1月29日，英矽智能涨近10%，高见66.5港元，再创历史新高，开年仅一个月公司已达成三笔重磅合作。
消息面上，开年仅一个月，英矽智能已达成三笔重磅合作。1月5日，公司与施维雅达成8.88亿美元研发合作，聚焦创新抗肿瘤疗法；1月20日，与深圳衡泰生物就ISM8969项目达成合作，加速推进全球开发，双方各持50%权益，英矽智能主导IND申报及I期临床试验；1月27日，与齐鲁制药达成超9.31亿港元合作，关注代谢疾病领域新颖小分子药物设计与优化。
浙商证券发布研报称，AI制药核心价值在于大幅提升药物早研效率，以英矽智能Pharma.AI为例，其能够使候选药物从靶点发现到临床前候选药物确认时间从4.5年大幅缩短到12至18个月，早研阶段的投入产出比大幅提升。该行指出，国内多家AI制药平台服务能力全球领先，海外业务拓展持续高速已验证，关注英矽智能等。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
